Central Pharmaceutical Joint Stock Company No3 (DP3) Q1 2025 earnings summary

Executive summary

• Net revenue for Q1 2025 was VND 91.9 billion, down 11.3% year-over-year; net profit after tax reached VND 23.86 billion, up 8.3% year-over-year.

• Operating profit increased to VND 29.57 billion from VND 27.05 billion in Q1 2024.

• Cash flow from operations turned positive at VND 23.38 billion, compared to negative VND 8.43 billion in the prior year.

Financial highlights

• Gross profit margin improved as cost of goods sold decreased to VND 31.04 billion from VND 32.94 billion year-over-year.

• Selling and administrative expenses dropped significantly to VND 32.49 billion from VND 44.67 billion year-over-year.

• Basic EPS for Q1 2025 was VND 1,110, up from VND 1,025 in Q1 2024.

• Cash and cash equivalents at quarter-end were VND 13.71 billion, up from VND 1.89 billion at the start of the year.

• Total assets increased to VND 648.6 billion from VND 607.8 billion at the start of the year.

Outlook and guidance

• No explicit forward-looking guidance provided, but strong cash flow and profit growth position the company for continued stability.